Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

New England Journal of Medicine

Volumn 344, Issue 14, 2001, Pages 1038-1042

  Druker, Brian J ^a   Sawyers, Charles L ^b   Kantarjian, Hagop ^c   Resta, Debra J ^d   Reese, Sofia Fernandes ^d   Ford, John M ^d   Capdeville, Renaud ^d   Talpaz, Moshe ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BCR ABL TYROSINE KINASE INHIBITOR; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL CRISIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG TOLERABILITY; EDEMA; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RELAPSE; REMISSION; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BLAST CRISIS; BLOOD CELL COUNT; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; PHILADELPHIA CHROMOSOME; PILOT PROJECTS; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECURRENCE; REMISSION INDUCTION;

EID: 0035810142     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200104053441402     Document Type: Article

References (20)

1. The biology of chronic myeloid leukemia
2. Chronic myeloid leukemia
3. Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
4. Chronic myelogenous leukemia in nonlymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients
5. Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high-dose decadron
6. Allogeneic bone marrow transplantation for chronic myeloid leukemia
7. Marrow transplantation for CML: The seattle experience
8. The biology and treatment of acute lymphoblastic leukemia in adults
9. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: A cancer and leukemia group B study (8762)
10. Outcome of treatment in children with Philadelphia chromosome - Positive acute lymphoblastic leukemia
11. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
12. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
13. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
14. Options for therapy in chronic myeloid leukaemia
15. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells
16. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs
17. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
18. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
19. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification